Tenofovir Disoproxil Global Market Report 2025

The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be credited to increased awareness and early detection of viral infections, the rising prevalence of hepatitis B infections, the expansion of generic drug manufacturing for tenofovir disoproxil, a growing number of clinical trials supporting its efficacy, and increased healthcare funding for infectious disease treatment.

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be credited to the rising demand for long-acting tenofovir formulations, an increasing focus on combination therapies with newer antivirals, growing regulatory approvals for novel tenofovir combinations, a heightened emphasis on pediatric formulations, and the increasing use of tenofovir in post-exposure prophylaxis. Key trends include the development of novel drug delivery systems, the integration of artificial intelligence in drug development, advancements in combination therapies, innovations in nanotechnology-based delivery, and progress in fixed-dose combination therapies.

The increasing prevalence of HIV and AIDS is expected to drive the growth of the tenofovir disoproxil market. HIV and AIDS are chronic viral infections that weaken the immune system by attacking CD4 cells, making the body more susceptible to infections and diseases. The rising prevalence of these conditions is attributed to factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and the emergence of drug-resistant virus strains. The growing number of HIV and AIDS cases is increasing the demand for tenofovir disoproxil, a key antiretroviral drug used for treatment and prevention. For example, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, reported that by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections recorded that year. Additionally, in 2022, around 630,000 deaths from AIDS-related illnesses occurred globally, with the number of people living with HIV rising to 39.9 million (36.1 million-44.6 million) in 2023. As a result, the increasing prevalence of HIV and AIDS is fueling the growth of the tenofovir disoproxil market.

The growing prevalence of hepatitis B is also expected to contribute to the expansion of the tenofovir disoproxil market. Hepatitis B is a viral infection that targets the liver and can lead to both acute and chronic disease, transmitted through contact with infected blood or bodily fluids. Factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations are driving the rise in hepatitis B cases. Tenofovir disoproxil is a widely used treatment for chronic hepatitis B, helping to suppress viral replication and minimize liver damage. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, estimated that between 580,000 and 2.4 million people in the United States are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Consequently, the increasing prevalence of hepatitis B is contributing to the demand for tenofovir disoproxil.

Leading companies in the tenofovir disoproxil market are focusing on innovative formulations, such as combination therapies, to enhance HIV/AIDS treatment and maintain a competitive edge. Combination therapy involves the simultaneous use of two or more treatments to improve therapeutic outcomes and patient well-being. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease. The FDA’s approval was based on data from a Phase II clinical trial demonstrating the drug’s safety and efficacy in children as young as six years old.

Major players in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd.

North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tenofovir disoproxil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tenofovir disoproxil is a medication used for treating HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it converts into its active form in the body, inhibiting viral replication. It belongs to the nucleotide reverse transcriptase inhibitors (NRTIs) class, which blocks a crucial enzyme required for viral multiplication.

The primary forms of tenofovir disoproxil are tablets and powder. Tablets are solid medicinal forms designed for easy swallowing, dissolving in the digestive system to release the active ingredient either gradually or immediately. The medication is distributed through online pharmacies, retail pharmacies, and wholesalers or distributors, with applications primarily in hospitals and clinics.

The tenofovir disoproxil market research report is one of a series of new reports that provides tenofovir disoproxil market statistics, including the tenofovir disoproxil industry's global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.